This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT) | MicrobiomeTrials
← Back to trials NCT07585968
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT) Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06Est. Completion: 2028-03
Enrollment target: 260 participantsOther microbiome trials you might be interested in Sustained Monomorphic VT (MMVT) Recurrent Ventricular Tachycardia
This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guide…
Phoenix, United States Est. completion Apr 30, 2028
Diffuse Large B-cell Lymphoma (DLBCL) Cardiotoxicity Lymphoma
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart fail…
Boston, United States Est. completion Dec 31, 2030
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety…
Multiple Locations Est. completion Dec 2027